Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Next Previous
X
Search
Trial Profile

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Onvapegleukin alfa (Primary) ; Pembrolizumab (Primary) ; TransCon TLR7/8 Agonist (Primary) ; Docetaxel; Paclitaxel; Pemetrexed
  • Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Malignant melanoma; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Acronyms IL Believe
  • Sponsors Ascendis Pharma

    • Most Recent Events

    • 08 Oct 2024 Planned End Date changed from 1 Aug 2027 to 1 Aug 2029.
    • 08 Oct 2024 Planned primary completion date changed from 1 May 2026 to 1 Aug 2027.
    • 13 Sep 2024 According to Ascendis Pharma media release, Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of this trial at ESMO 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top